Compare Iris Energy Limited (IREN) vs Moderna, Inc. (MRNA) Price & Performance

IREN stock trades at $43.17, up 11.44% today amid positive AI infrastructure news. The technical picture is neutral with resistance near $42. Fundamentally, the company shows strong revenue growth to $501M in 2025 and has secured $2.8B in new AI contracts, though it has missed recent EPS estimates and reports negative ROE and ROA. Analyst sentiment is bullish with a $84.43 price target.

Outlook is driven by AI cloud expansion but carries execution risks. The stock offers growth potential from its $4B revenue target, yet high valuations and recent earnings misses pose challenges. Investors should weigh contract momentum against profitability concerns and sector volatility.

Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.

The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.